Trialing Outpatient Treatments for Moderate COVID Cases | COVID-19 Media Briefing скачать в хорошем качестве

Trialing Outpatient Treatments for Moderate COVID Cases | COVID-19 Media Briefing

A new study led by the Duke Clinical Research Institute is looking at whether three existing medications would treat mild-to-moderate COVID-19 effectively. (More information on the study is available here.) The three repurposed medications, already approved by the U.S. Food and Drug Administration for other uses, are: Ivermectin, used to treat parasitic infections; Fluticasone, an inhaled steroid commonly prescribed for asthma and chronic obstructive pulmonary disease; and Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), often prescribed for depression. On Tuesday, institute executive director Adrian Hernandez discussed the study with reporters in a virtual media briefing, where he touched on the need for COVID-19 therapies and making it easy for people across the country to take part in the study. Read more ➡ https://today.duke.edu/2021/08/why-co... 𝐓𝐡𝐞 𝐏𝐚𝐧𝐞𝐥𝐢𝐬𝐭 Adrian Hernandez, M.D., is a cardiologist, vice dean of the Duke University School of Medicine and executive director of the Duke Clinical Research Institute, where he oversees clinical research programs, clinical trials and clinical education. 𝐌𝐞𝐝𝐢𝐚 𝐁𝐫𝐢𝐞𝐟𝐢𝐧𝐠𝐬 This video is part of a series of media briefings where Duke experts speak on current issues. Media Briefings Playlist ➡ http://duke.is/RA7pNR 𝐀𝐛𝐨𝐮𝐭 𝐃𝐮𝐤𝐞 𝐔𝐧𝐢𝐯𝐞𝐫𝐬𝐢𝐭𝐲 A private research university located in Durham, North Carolina, Duke University is known as one of the world’s leading institutions for education, research, and patient care. Subscribe ➡ http://duke.is/zUTmxY 𝐅𝐨𝐥𝐥𝐨𝐰 #𝐃𝐮𝐤𝐞𝐔𝐧𝐢𝐯𝐞𝐫𝐬𝐢𝐭𝐲 Home: https://duke.edu/ News: https://news.duke.edu/ Twitter:   / dukeu   Instagram:   / dukeuniversity   Facebook:   / dukeuniv